Latanoprost
Unchecked
Latanoprost
Xalatan, Xelpros
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Primary open-angle glaucoma0, Ocular hypertension0
Pharmacy
Starting dose
1 drop in the affected eye(s) once daily in the evening
Preparations
0.005% ophthalmic solution (50 mcg/mL); typical 2.5 mL bottle
US FDA Max
1 drop/eye/day (more frequent dosing reduces efficacy)
Pharmacology
Routes
Topical ophthalmic
Onset
IOP lowering at 3-4 hours; maximum at 8-12 hours
Duration
24 hours
Half-life
~17 minutes (free acid, the active form, in aqueous humor)[1]
Bioavailability
Topical; minimal systemic absorption[1]
Pregnancy
Limited data; weigh against alternatives, though systemic exposure is low.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Latanoprost is an isopropyl ester prodrug hydrolyzed in the cornea to its free acid, a selective FP-receptor (prostaglandin F2α receptor) agonist; FP activation remodels the ciliary muscle extracellular matrix and increases uveoscleral aqueous outflow, lowering intraocular pressure by ~25-35%.0 Once-daily evening dosing is more effective than morning. Characteristic adverse effects: iris pigmentation darkening (especially mixed-color irides; permanent), periocular skin pigmentation, eyelash growth (used cosmetically for the closely-related bimatoprost), conjunctival hyperemia[1].
References
[edit | edit source]- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Xalatan (latanoprost), Pfizer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020597s056lbl.pdf